same drug, different label) If you have moderate obesity (BMI 30 to 35): Semaglutide (Ozempic for diabetes, Wegovy for obesity) or liraglutide (Victoza for diabetes, Saxenda for obesity) If you want the simplest regimen: Once-weekly semaglutide or tirzepatide Goal: Minimize injection frequency Once weekly: Semaglutide, tirzepatide, dulaglutide, efpeglenatide, retatrutide Every two weeks (pipeline): Ecnoglutide (pending approval) Oral (no injections): Semaglutide (Rybelsus) or orforglipron (Orfoglip) Goal: Minimize gastrointestinal side effects Lower nausea profile: Tirzepatide (dual agonist
In total, 88 (72%) malignant peripheral nerve sheath tumors, including 46 (71%) NF1-associated, 4 (100%) radiation-associated, and 38 (72%) sporadic tumors, showed complete loss of H3K27me3
The FDA oversees the approval and labeling of prescription peptides, while the DEA regulates the distribution and use of controlled substances [5]
Its clinical adoption is significantly hampered by practical limitations, including an intravenous-only administration route unsuitable for long-term or outpatient care and a narrow therapeutic window
